Galenicap enters into drug reformulation program with Dutch university

​

Clozathera BV, a Galenicap company, announced the filing of a new patent application

Galenicap enters in research collaboration with German university

Galenicap enters into development collaboration with Canadian drug development company

Galenicap to create two new SPVs: Clozathera BV (schizoprenia) and Mexthera BV (cardiovascular diseases)

Hans Platteeuw, Galenicap's CSO, to give keynote at Spark Europe Webinar "What is Drug Repurposing and Why is it Relevant"

Galenicap announces new collaboration with Dutch university and Dutch specialty pharma company

Galenicap enters into development collaboration with two German drug development companies

Galenicap to enter into research collaboration with German university and Spanish specialty pharma company

For more information about our news items, feel free to get in touch

​

Galenicap enters into drug reformulation co-development agreement with Germany pharma company

Galenicap to join the REMEDi4ALL Funders Network (click here for more information)

Galenicap closes research collaboration with Dutch University and Dutch drug development company

Galenicap closes collaboration with Japanese university on repurposing project in fibrosis space.